The cart was before the horse before. They truly have great IP just a really incompetent CEO. I truly believe that in the end the science wins out over their incompetence just like it did with Medistem. They are doing all of the hard work now to make it turnkey because they know running daily operations and executing business plans is not what they do. IP + Development IP + Commercialization = $. Lots of biotechs out there and I haven't come across any that have this much workable IP. Despite of themselves and their incompetence this is still a long hold.
Market Data 
Markets 
AI
